Egypt
Tuberculosis profile
Population  2013 82 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.55 (0.49–0.62) 0.67 (0.6–0.75)
Mortality (HIV+TB only) 0.034 (0.013–0.064) 0.04 (0.02–0.08)
Prevalence  (includes HIV+TB) 22 (12–36) 27 (14–44)
Incidence  (includes HIV+TB) 13 (12–15) 16 (15–18)
Incidence (HIV+TB only) 0.097 (0.017–0.18) 0.12 (0.02–0.22)
Case detection, all forms (%) 59 (53–65)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.4 (1.9–4.9) 15 (12–18)
MDR-TB cases among notified pulmonary
TB cases
170 (94–240) 97 (78–120)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 906   342
Pulmonary, clinically diagnosed 63   0
Extrapulmonary 2 565   0
       
Total new and relapse 7 876    
Previously treated, excluding relapses 307    
Total cases notified 8 183    
Among 7 534 new cases:
512 (7%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 41 (<1%) 516 (80%) 557
Laboratory-confirmed RR-/MDR-TB cases     119
Patients started on MDR-TB treatment     57
TB/HIV 2013 Number (%)
TB patients with known HIV status 783 (10)
HIV-positive TB patients 7 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 7 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 88
Previously treated cases registered in 2012 61
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 68
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-05 Data: www.who.int/tb/data